A patent review of BRD4 inhibitors (2020-present)
文献类型：期刊论文
| 作者 | Chen, Yanfang5; Zhou, Huanmin4; Yu, Jiamin2,3; Gao, Jing5; Xue, Shengyu2,3; Ding, Hong2 ; Lin, Hua5; Luo, Cheng1,2,3,4
|
| 刊名 | EXPERT OPINION ON THERAPEUTIC PATENTS
 |
| 出版日期 | 2025-02-15 |
| 页码 | 16 |
| 关键词 | BET BRD4 inhibitor cancer treatment selectivity |
| ISSN号 | 1354-3776 |
| DOI | 10.1080/13543776.2025.2463150 |
| 英文摘要 | IntroductionBromodomain-containing protein 4 (BRD4) stands as a pivotal member within the Bromodomain and Extra-Terminal Domain (BET) family, contributing significantly to epigenetic control and gene expression. Given its association with various cancers, BRD4 emerges as a promising therapeutic target, suggesting a substantial role in the treatment of diverse pathological conditions.Areas coveredThe present review is centered on patent applications concerning inhibitors targeting BRD4's bromodomain site, published from 2020 to present. A comprehensive evaluation was conducted on a total of 70 applications. The latest patented studies of BRD4 are summarized by using the keywords 'BRD4' in SciFinder, PubMed, and The lens Patents and databases in the year from 2020 to present.Expert opinionDespite the substantial progress achieved in the clinical research of numerous BET bromodomain inhibitors, their development remains fraught with challenges. To mitigate the dose-limiting toxicity (DLT) and other clinical adverse effects associated with pan-BET inhibitors, current research efforts are increasingly focus on the development of selective BRD4-BD1 or -BD2 inhibitors. These selective inhibitors exhibit considerable potential as more efficacious candidate drugs, thereby paving the way for novel avenues in both fundamental and translational research within this domain. |
| WOS关键词 | BROMODOMAIN PROTEIN BRD4 ; CANCER-CELLS ; P-TEFB ; BET ; TARGET ; MYC ; DEGRADATION ; IDENTIFICATION ; DROSOPHILA ; CARCINOMA |
| 资助项目 | National Key R&D Program of China[2022YFC3400500] ; National Natural Science Foundation of China[22377013] ; National Natural Science Foundation of China[81821005] ; National Natural Science Foundation of China[U23A20108] ; National Natural Science Foundation of China[92253303] ; State Key Laboratory of Drug Research[SKLDR-2023-KF-07] ; Science and Technology Commission of Shanghai Municipality[YDZX20233100004032] ; Project of National Multidisciplinary Innovation Team of Traditional Chinese Medicine by National Administration of Traditional Chinese Medicine[ZYYCXTD202004] ; Major Program of Guangzhou National Laboratory[GZNL2023A02012] ; High-level New RD Institute[2019B090904008] ; High-level Innovative Research Institute[2021B0909050003] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001421094300001 |
| 出版者 | TAYLOR & FRANCIS LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/316215]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Luo, Cheng |
| 作者单位 | 1.Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China 3.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing, Peoples R China 4.Fujian Med Univ, Sch Pharm, Fuzhou, Peoples R China 5.Fujian Normal Univ, Key Lab Microbial Pathogenesis & Intervent Fujian, Coll Life Sci, Biomed Res Ctr South China,Key Lab Innate Immune B, Fuzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chen, Yanfang,Zhou, Huanmin,Yu, Jiamin,et al. A patent review of BRD4 inhibitors (2020-present)[J]. EXPERT OPINION ON THERAPEUTIC PATENTS,2025:16. |
| APA | Chen, Yanfang.,Zhou, Huanmin.,Yu, Jiamin.,Gao, Jing.,Xue, Shengyu.,...&Luo, Cheng.(2025).A patent review of BRD4 inhibitors (2020-present).EXPERT OPINION ON THERAPEUTIC PATENTS,16. |
| MLA | Chen, Yanfang,et al."A patent review of BRD4 inhibitors (2020-present)".EXPERT OPINION ON THERAPEUTIC PATENTS (2025):16. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。